Vertex Secures Phase II Win In Rare Kidney Condition
Sparks Pivotal Development Plans For VX-147
Executive Summary
The firm’s sole nephrological asset has demonstrated proof of concept, helping advance the novel gene-targeted therapy into pivotal development early next year.
You may also be interested in...
Beyond Aduhelm: OIG Review Will Put FDA’s Entire Accelerated Approval Program Under Microscope
HHS Inspector General’s timeline means Congress won’t have findings to use during upcoming user fee renewal debate; ‘review’ is not an ‘investigation’ which could come with potentially more damning legal consequences for the agency.
Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.